BACKGROUND: The JAK2V617F mutation has been associated with constitutive and enhanced activation of neutrophils, while no information is available concerning other leukocyte subtypes. DESIGN AND METHODS: We evaluated correlations between JAK2V617F mutation and the count of circulating basophils, the number of activated CD63(+) basophils, their response in vitro to agonists as well as the effects of a JAK2 inhibitor. RESULTS: We found that basophil count was increased in patients with JAK2V617F -positive myeloproliferative neoplasms, particularly in those with polycythemia vera, and was correlated with the V617F burden. The burden of V617F allele was similar in neutrophils and basophils from patients with polycythemia vera, while total JAK2 mRNA content was remarkably greater in the basophils; however, the content of JAK2 protein in basophils was not increased. The number of CD63(+) basophils was higher in patients with polycythemia vera than in healthy subjects or patients with essential thrombocythemia or primary myelofibrosis and was correlated with the V617F burden. Ultrastructurally, basophils from patients with polycythemia vera contained an increased number of granules, most of which were empty suggesting cell degranulation in vivo. Ex vivo experiments revealed that basophils from patients with polycythemia vera were hypersensitive to the priming effect of interleukin-3 and to f-MLP-induced activation; pre-treatment with a JAK2 inhibitor reduced polycythemia vera basophil activation. Finally, we found that the number of circulating CD63(+) basophils was significantly greater in patients suffering from aquagenic pruritus, who also showed a higher V617F allele burden. CONCLUSIONS: These data indicate that the number of constitutively activated and hypersensitive circulating basophils is increased in polycythemia vera, underscoring a role of JAK2V617F in these cells' abnormal function and, putatively, in the pathogenesis of pruritus.
BACKGROUND: The JAK2V617F mutation has been associated with constitutive and enhanced activation of neutrophils, while no information is available concerning other leukocyte subtypes. DESIGN AND METHODS: We evaluated correlations between JAK2V617F mutation and the count of circulating basophils, the number of activated CD63(+) basophils, their response in vitro to agonists as well as the effects of a JAK2 inhibitor. RESULTS: We found that basophil count was increased in patients with JAK2V617F -positive myeloproliferative neoplasms, particularly in those with polycythemia vera, and was correlated with the V617F burden. The burden of V617F allele was similar in neutrophils and basophils from patients with polycythemia vera, while total JAK2 mRNA content was remarkably greater in the basophils; however, the content of JAK2 protein in basophils was not increased. The number of CD63(+) basophils was higher in patients with polycythemia vera than in healthy subjects or patients with essential thrombocythemia or primary myelofibrosis and was correlated with the V617F burden. Ultrastructurally, basophils from patients with polycythemia vera contained an increased number of granules, most of which were empty suggesting cell degranulation in vivo. Ex vivo experiments revealed that basophils from patients with polycythemia vera were hypersensitive to the priming effect of interleukin-3 and to f-MLP-induced activation; pre-treatment with a JAK2 inhibitor reduced polycythemia vera basophil activation. Finally, we found that the number of circulating CD63(+) basophils was significantly greater in patients suffering from aquagenic pruritus, who also showed a higher V617F allele burden. CONCLUSIONS: These data indicate that the number of constitutively activated and hypersensitive circulating basophils is increased in polycythemia vera, underscoring a role of JAK2V617F in these cells' abnormal function and, putatively, in the pathogenesis of pruritus.
Authors: Ayalew Tefferi; Terra L Lasho; Susan M Schwager; Jacob S Strand; Michelle Elliott; Ruben Mesa; Chin-Yang Li; Martha Wadleigh; Stephanie J Lee; D Gary Gilliland Journal: Cancer Date: 2006-02-01 Impact factor: 6.860
Authors: S Temerinac; S Klippel; E Strunck; S Röder; M Lübbert; W Lange; M Azemar; G Meinhardt; H E Schaefer; H L Pahl Journal: Blood Date: 2000-04-15 Impact factor: 22.113
Authors: Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi Journal: J Clin Oncol Date: 2011-01-04 Impact factor: 44.544
Authors: John S Tokarski; Adriana Zupa-Fernandez; Jeffrey A Tredup; Kristen Pike; ChiehYing Chang; Dianlin Xie; Lihong Cheng; Donna Pedicord; Jodi Muckelbauer; Stephen R Johnson; Sophie Wu; Suzanne C Edavettal; Yang Hong; Mark R Witmer; Lisa L Elkin; Yuval Blat; William J Pitts; David S Weinstein; James R Burke Journal: J Biol Chem Date: 2015-03-11 Impact factor: 5.157
Authors: Mary F F McMullin; Adam J Mead; Sahra Ali; Catherine Cargo; Frederick Chen; Joanne Ewing; Mamta Garg; Anna Godfrey; Steven Knapper; Donal P McLornan; Jyoti Nangalia; Mallika Sekhar; Frances Wadelin; Claire N Harrison Journal: Br J Haematol Date: 2018-11-13 Impact factor: 6.998